Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126479483 | 12647948 | 3 | F | 201604 | 20160829 | 20160812 | 20160909 | EXP | GB-TEVA-683074ACC | TEVA | 41.00 | YR | F | Y | 0.00000 | 20160909 | OT | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126479483 | 12647948 | 1 | SS | DOCETAXEL. | DOCETAXEL | 1 | Unknown | UNK | U | U | 0 | ||||||||
126479483 | 12647948 | 2 | SS | EPIRUBICIN | EPIRUBICIN | 1 | UNK | U | U | 0 | |||||||||
126479483 | 12647948 | 3 | PS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | UNK | U | U | 77255 | |||||||||
126479483 | 12647948 | 4 | SS | METOCLOPRAMIDE. | METOCLOPRAMIDE | 1 | Unknown | UNK | U | U | 70184 | ||||||||
126479483 | 12647948 | 5 | SS | NEULASTA | PEGFILGRASTIM | 1 | Unknown | UNK | U | U | 0 | ||||||||
126479483 | 12647948 | 6 | SS | TAXOTERE | DOCETAXEL | 1 | Unknown | UNK | U | U | 0 | ||||||||
126479483 | 12647948 | 7 | SS | APREPITANT. | APREPITANT | 1 | Oral | DOSAGE - 168 (UNITS UNSPECIFIED) | U | U | 0 | POWDER | |||||||
126479483 | 12647948 | 8 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | UNK | U | U | 0 | |||||||||
126479483 | 12647948 | 9 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | UNK | U | U | 0 | TABLET | |||||||
126479483 | 12647948 | 10 | SS | DOMPERIDONE | DOMPERIDONE | 1 | UNK | U | U | 0 | |||||||||
126479483 | 12647948 | 11 | SS | PALONOSETRON HYDROCHLORIDE. | PALONOSETRON HYDROCHLORIDE | 1 | UNK | U | U | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126479483 | 12647948 | 1 | Product used for unknown indication |
126479483 | 12647948 | 2 | Product used for unknown indication |
126479483 | 12647948 | 3 | Product used for unknown indication |
126479483 | 12647948 | 4 | Product used for unknown indication |
126479483 | 12647948 | 5 | Product used for unknown indication |
126479483 | 12647948 | 6 | Product used for unknown indication |
126479483 | 12647948 | 7 | Product used for unknown indication |
126479483 | 12647948 | 8 | Product used for unknown indication |
126479483 | 12647948 | 9 | Product used for unknown indication |
126479483 | 12647948 | 10 | Product used for unknown indication |
126479483 | 12647948 | 11 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126479483 | 12647948 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126479483 | 12647948 | Alopecia | |
126479483 | 12647948 | Ear discomfort | |
126479483 | 12647948 | Epistaxis | |
126479483 | 12647948 | Fatigue | |
126479483 | 12647948 | Haemoglobin abnormal | |
126479483 | 12647948 | Infusion site erythema | |
126479483 | 12647948 | Infusion site pruritus | |
126479483 | 12647948 | Infusion site vesicles | |
126479483 | 12647948 | Joint swelling | |
126479483 | 12647948 | Limb discomfort | |
126479483 | 12647948 | Neuropathy peripheral | |
126479483 | 12647948 | Oedema peripheral | |
126479483 | 12647948 | Pain in extremity | |
126479483 | 12647948 | Peripheral swelling | |
126479483 | 12647948 | Pyrexia | |
126479483 | 12647948 | Rosacea | |
126479483 | 12647948 | Thrombosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126479483 | 12647948 | 1 | 20160602 | 0 | ||
126479483 | 12647948 | 5 | 20160603 | 0 | ||
126479483 | 12647948 | 6 | 20160602 | 0 |